Skip to main content

Table 1 Patient characteristics

From: Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis

Group Gender Age Diagnosis Age at diagnosis IS
1 f 9 CD 3 Sirolimus 0.1 mg/kg/day
(10.4 ng/ml blood level)
1 m 14 UC 11 Vedolizumab 300 mg/8 weeks
1 m 17 UC 15 Adalimumab 40 mg/week
(11.57 μg/ml blood level)
1 f 12 CD 8 Adalimumab 40 mg/week
(10.35 μg/ml blood level)
1 m 16 CD 3 Adalimumab 40 mg/2 weeks
(6.5 μg/ml blood level)
1 m 14 UC 12 Adalimumab 40 mg/week
(12.35 μg/ml blood level)
Tacrolimus 0.12 mg/kg/day
(2.6 ng/ml blood level)
AZA 1.0 mg/kg/day
1 f 11 UC 10 Infliximab 5 mg/kg/4 weeks
(4.66 μg/ml blood level)
1 f 18 UC 17 Vedolizumab 300 mg/8 weeks
AZA 2.6 mg/kg/day
Sirolimus 0.18 mg/kg/day
(8.8 ng/ml blood level)
Prednisolone 0.5 mg/kg/day
1 f 15 UC 10 Adalimumab 40 mg/4 weeks
(6.5 μg/ml blood level)
1 m 5 CD 3 Infliximab 10 mg/kg/4 weeks
(0.5 μg/ml blood level)
Tacrolimus 0.19 mg/kg/day
(30.9 ng/ml blood level)
1 f 14 CD 13 Infliximab 5 mg/kg/4 weeks
(3.36 μg/ml blood level)
1 m 14 CD 13 Infliximab 5 mg/kg/6 weeks
(1.56 μg/ml blood level)
AZA 2.1 mg/kg/d
1 m 9 UC 6 Infliximab 5 mg/kg/6–8 weeks
(1.03 μg/ml blood level)
AZA 2.2 mg/kg/day
1 f 10 UC 5 Vedolizumab 250 mg/8 weeks
1 m 12 CD 12 Infliximab 5 mg/kg/8 weeks
(0.94 μg/ml blood level)
1 m 11 CD 4 Golimumab 50 mg/4 weeks
(8.5 μg/ml blood level)
1 m 15 CD 13 Infliximab 5 mg/kg/4 weeks
(14.2 μg/ml blood level)
2 f 10 CD 8 AZA 2.3 mg/kg/day
2 f 9 UC 1 AZA 2.2 mg/kg/day
2 m 18 CD 16 AZA 1.9 mg/kg/day
2 f 17 CD 3 AZA 1.9 mg/kg/day
2 f 13 AIH 4 AZA 1 mg/kg/day
2 m 17 AIH 10 AZA 1.7 mg/kg/day
2 f 16 AIH 12 AZA 1.1 mg/kg/day
2 f 9 UC 5 Tacrolimus 0.23 mg/kg/day
(4.5 ng/ml blood level)
3 f 13 CD 12 No IS
3 m 15 CD 3 No IS
3 f 3 CD 3 No IS
3 m 14 UC 2 No IS
3 f 15 UC 10 No IS
3 m 12 CD 12 No IS